<DOC>
	<DOCNO>NCT02425176</DOCNO>
	<brief_summary>The efficacy Botulinum toxin A ( BoNT-A ) Asian population properly study literature available efficacious dose BoNT-A sialorrhoea treatment . This research aim find dose Dysport® would efficacious without treatment-related adverse event duration effectiveness drug sialorrhea treatment Malaysian patient . The efficacy , safety , tolerability adverse effect three dos Dysport® ( 50MU , 100MU 200MU ) examine 2,6,12 24 week post injection double-blinding , randomize trial .</brief_summary>
	<brief_title>Botulinum Toxin-A Sialorrhoea Treatment Asian Adults With Neurological Diseases</brief_title>
	<detailed_description>Study Objectives : To determine efficacy , safety , tolerability adverse effect three dos Dysport® ( 50MU , 100MU 200MU ) treatment sialorrhoea Asian patient neurological disorders/diseases determine efficacious dose . Study design : Dose-ranging double blind pilot study . Sample size : At least 30 adult patient various neurological disorder complicate sialorrhoea include stroke , motor neurone disease , traumatic brain injury Parkinsonism would divide 3 dose group . Study method : Patients satisfy inclusion criterion give informed consent would randomize 3 equal group give different total doses-50MU , 100MU , 200MU . The total dose divide equally give 4 salivary gland viz . submandibular parotid gland bilaterally . For example , 200MU give total , 50MU would give gland . Injections would give via 25G needle gland ultrasound guidance well needle placement . One site inject per gland . Primary outcome measure The percentage reduction rate saliva production ( measure difference mean weight dental roll per minute baseline ) group give different dos Dysport® 2,6,12 24 week post injection . Secondary outcome measure 1 . Patient 's subjective assessment improvement sialorrhoea use Drooling Frequency Severity Scale ( Thomas-Stonell scale ) 2,6,12 24 week post-injection . 2 . Duration maximum reduction salivation ( measure maximum reduction weight dental roll )</detailed_description>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Patients ≥ 18 year old . 2 . Patients neurological disorder include stroke , motor neurone disease , traumatic brain injury Parkinsonism , diagnosis confirm clinically treat physician . 3 . Patients ThomasStonell Drooling Frequency Severity Scale combine drool rank ≥5 . 4 . Patients able give sign informed consent willing able comply schedule visit , treatment plan study procedure . 1 . Patients pregnant . 2 . Patients bleed disorder anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>botulinum toxin</keyword>
	<keyword>sialorrhoea</keyword>
	<keyword>drool</keyword>
</DOC>